Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer

References

• Adlakha-Hutcheon G, Bally MB, Shew CR, Madden TD. (1999). Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat Biotechnol 17:775–9
   PubMed Web of Science ®Google Scholar
• André F, Zielinski CC. (2012). Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol 23:vi46–51
   PubMed Web of Science ®Google Scholar
• Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM. (2015). Therapies for triple negative breast cancer. Expert Opin Pharmacother 16:983–98
   PubMed Web of Science ®Google Scholar
• Bonotto M, Gerratana L, Poletto E, et al. (2014). Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist 19:608–15
   PubMed Web of Science ®Google Scholar
• Cai L, Qiu N, Xiang M, et al. (2014). Improving aqueous solubility and antitumor effects by nanosized gambogic acid-mPEG2000 micelles. Int J Nanomedicine 9:243–55
   PubMed Web of Science ®Google Scholar
• Chang HI, Yeh MK. (2012). Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 7:49–60
   PubMed Web of Science ®Google Scholar
• Deshpande PP, Biswas S, Torchilin VP. (2013). Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond) 8:1509–28
   PubMed Web of Science ®Google Scholar
• Doddapaneni R, Chawla YK, Das A, et al. (2013). Overexpression of microRNA-122 enhances in vitro hepatic differentiation of fetal liver-derived stem/progenitor cells. J Cell Biochem 114:1575–83
   PubMed Web of Science ®Google Scholar
• Godugu C, Patel AR, Doddapaneni R, et al. (2014). Approaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid. PLoS One 9:e89919
   PubMed Web of Science ®Google Scholar
• Gu H, Rao S, Zhao J, et al. (2009). Gambogic acid reduced bcl-2 expression via p53 in human breast MCF-7 cancer cells. J Cancer Res Clin Oncol 135:1777–82
   PubMed Web of Science ®Google Scholar
• Immordino ML, Dosio F, Cattel L. (2006). Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1:297–315
   PubMed Web of Science ®Google Scholar
• Li C, Lu N, Qi Q, et al. (2011). Gambogic acid inhibits tumor cell adhesion by suppressing integrin β1 and membrane lipid rafts-associated integrin signaling pathway. Biochem Pharmacol 82:1873–83
   PubMed Web of Science ®Google Scholar
• Li C, Qi Q, Lu N, et al. (2012). Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells. Biochem Cell Biol 90:718–30
   PubMed Web of Science ®Google Scholar
• Liu YT, Hao K, Liu XQ, Wang GJ. (2006). Metabolism and metabolic inhibition of gambogic acid in rat liver microsomes. Acta Pharmacol Sin 27:1253–8
   PubMed Web of Science ®Google Scholar
• Lu N, Hui H, Yang H, et al. (2013). Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1α pathway. Eur J Pharm Sci 49:220–6
   PubMed Web of Science ®Google Scholar
• Lu N, Yang Y, You QD, et al. (2007). Gambogic acid inhibits angiogenesis through suppressing vascular endothelial growth factor-induced tyrosine phosphorylation of KDR/Flk-1. Cancer Lett 258:80–9
   PubMed Web of Science ®Google Scholar
• Misso G, Di Martino MT, De Rosa G, et al. (2014). Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids 3:e194. doi: 10.1038/mtna.2014.47
   PubMedGoogle Scholar
• Naithani R, Huma LC, Moriarty RM, et al. (2008). Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem 15:1044–71
   PubMed Web of Science ®Google Scholar
• Palmer JR, Viscidi E, Troester MA, et al. (2014). Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium. J Natl Cancer Inst 106:dju237. doi: 10.1093/jnci/dju237
   PubMedGoogle Scholar
• Patel K, Patil A, Mehta M, et al. (2013). Medium chain triglyceride (MCT) rich, paclitaxel loaded self nanoemulsifying preconcentrate (PSNP): a safe and efficacious alternative to Taxol. J Biomed Nanotechnol 9:1996–2006
   PubMed Web of Science ®Google Scholar
• Patel K, Patil A, Mehta M, et al. (2014). Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity. Int J Pharm 472:214–23
   PubMed Web of Science ®Google Scholar
• Pereira WO, Amarante-Mendes GP. (2011). Apoptosis: a programme of cell death or cell disposal? Scand J Immunol 73:401–7
   PubMed Web of Science ®Google Scholar
• Qi Q, Gu H, Yang Y, et al. (2008a). Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis. J Mol Med (Berl) 86:1367–77
   PubMed Web of Science ®Google Scholar
• Qi Q, You Q, Gu H, et al. (2008b). Studies on the toxicity of gambogic acid in rats. J Ethnopharmacol 117:433–8
   PubMed Web of Science ®Google Scholar
• Sawant RR, Torchilin VP. (2012). Challenges in development of targeted liposomal therapeutics. AAPS J 14:303–15
   PubMed Web of Science ®Google Scholar
• Saxena V, Hussain MD. (2012). Poloxamer 407/TPGS mixed micelles for delivery of gambogic acid to breast and multidrug-resistant cancer. Int J Nanomedicine 7:713–21
   PubMed Web of Science ®Google Scholar
• Tao Z, Shi A, Lu C, et al. (2014). Breast cancer: epidemiology and etiology. Cell Biochem Biophys 72:333–8
   Web of Science ®Google Scholar
• Vaseva AV, Moll UM. (2009). The mitochondrial p53 pathway. Biochim Biophys Acta 1787:414–20
   PubMed Web of Science ®Google Scholar
• Wang X, Chen W. (2012). Gambogic acid is a novel anti-cancer agent that inhibits cell proliferation, angiogenesis and metastasis. Anticancer Agents Med Chem 12:994–1000
   PubMed Web of Science ®Google Scholar
• Xing M, Yan F, Yu S, Shen P. (2015). Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: a meta-analysis of ten randomized controlled trials. PLoS One 10:e0133569. doi: 10.1371/journal.pone.0133569
   PubMed Web of Science ®Google Scholar
• Xu J, Zhou M, Ouyang J, et al. (2013). Gambogic acid induces mitochondria-dependent apoptosis by modulation of Bcl-2 and Bax in mantle cell lymphoma JeKo-1 cells. Chin J Cancer Res 25:183–91
   PubMed Web of Science ®Google Scholar
• Yao J, Li Y, Sun X, et al. (2014). Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid. Int J Nanomedicine 9:3313–24
   PubMed Web of Science ®Google Scholar
• Zhai D, Jin C, Shiau CW, et al. (2008). Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther 7:1639–46
   PubMed Web of Science ®Google Scholar
• Zou ZY, Wei J, Li XL, et al. (2012). Enhancement of anticancer efficacy of chemotherapeutics by gambogic acid against gastric cancer cells. Cancer Biother Radiopharm 27:299–306
   PubMed Web of Science ®Google Scholar